EUVIMEDEUVIMED entdecken
Open Access

Curcumenol inhibits malignant progression and promotes ferroptosis via the SLC7A11/NF‑κB/TGF‑β pathway in triple‑negative breast cancer

Feifei Li, Qin Qi, Yu Qiao, Yan Huang, Yuan Lu, Kan Gu, Huirong Liu, Chunfang Gao, Sheng Liu, Huangan Wu

International Journal of Molecular Medicine · 14.05.2025 · 56 (1) · 1-18

DOI: 10.3892/ijmm.2025.5552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 14.05.2025. Verfasst von Feifei Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Laboratory, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Sha…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Ferroptosis, NF-kappa B, Transforming Growth Factor beta. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‑negative breast cancer (TNBC) exhibits a high degree of malignancy and a propensity for metastasis, ultimately resulting in unfavorable patient outcomes. Curcuma phaeocaulis Valeton is a common herb used in traditional Chinese medicine to treat TNBC. Curcumenol (Cur) is a natural compound derived from C. phaeocaulis Valeton, the effects of which on breast cancer remain under‑reported. The present study elucidated that Cur could effectively inhibit the survival ability of TNBC cells and enhance their sensitivity to paclitaxel. Western blotting (WB) further revealed that Cur modulated apoptosis and epithelial‑mesenchymal transition (EMT) in TNBC. Findings from animal experiments further validated these observations. In the established TNBC mouse model, Cur was shown to exert an inhibitory effect on tumor growth, effectively attenuate EMT and substantially reduce the incidence of lung metastasis. Integrated analyses using RNA sequencing, WB and reverse transcription‑quantitative polymerase chain reaction demonstrated that Cur markedly downregulated the expression levels of solute carrier family 7 member 11 (SLC7A11), phosphorylated‑NF‑κB and TGF‑β. Molecular docking studies further validated that Cur can establish stable interactions with SLC7A11. In‑depth bioinformatics analysis revealed a positive association between high SLC7A11 expression and reduced disease‑free survival in patients with breast cancer. Additionally, in TNBC cells, Cur was revealed to reduce the mitochondrial membrane potential and promote the accumulation of lipid reactive oxygen species. Subsequent experimental investigations demonstrated that Cur can counteract the inhibitory influence of ferrostatin‑1 on ferroptosis. These findings strongly implied a potential underlying mechanism, suggesting that Cur may impede the malignant progression of TNBC via the modulation of ferroptosis. In conclusion, the findings of the present study underscore the marked efficacy of Cur in hampering the progression of TNBC by suppressing the SLC7A11/NF‑κB/TGF‑β signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsFerroptosisNF-kappa BTransforming Growth Factor betaSignal TransductionAmino Acid Transport System y+SesquiterpenesHumansAnimalsFemaleCell Line, TumorMiceEpithelial-Mesenchymal TransitionDisease ProgressionMolecular Docking SimulationGene Expression Regulation, NeoplasticCell Proliferation

Stichwörter der Autor:innen

curcumenolepithelial‑mesenchymal transitionferroptosislung metastasistriple‑negative breast cancer

Substanzen

NF-kappa BTransforming Growth Factor betaSLC7A11 protein, humanAmino Acid Transport System y+Sesquiterpenes

Autor:innen und Institutionen

  • Medical Laboratory, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, P.R. China.
  • Hospital Management Office, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China.

Zitieren

APA

Li, F., Qi, Q., Qiao, Y., Huang, Y., Lu, Y., Gu, K., Liu, H., Gao, C., Liu, S., & Wu, H. (2025). Curcumenol inhibits malignant progression and promotes ferroptosis via the SLC7A11/NF‑κB/TGF‑β pathway in triple‑negative breast cancer. International Journal of Molecular Medicine, 56(1), 1-18. https://doi.org/10.3892/ijmm.2025.5552

Vancouver

Li F, Qi Q, Qiao Y, Huang Y, Lu Y, Gu K, et al. Curcumenol inhibits malignant progression and promotes ferroptosis via the SLC7A11/NF‑κB/TGF‑β pathway in triple‑negative breast cancer. International Journal of Molecular Medicine. 2025;56(1):1-18. doi:10.3892/ijmm.2025.5552

BibTeX
@article{Li2025,
  author = {Li, Feifei and Qi, Qin and Qiao, Yu and Huang, Yan and Lu, Yuan and Gu, Kan and Liu, Huirong and Gao, Chunfang and Liu, Sheng and Wu, Huangan},
  title = {Curcumenol inhibits malignant progression and promotes ferroptosis via the SLC7A11/NF‑κB/TGF‑β pathway in triple‑negative breast cancer},
  journal = {International Journal of Molecular Medicine},
  year = {2025},
  volume = {56},
  number = {1},
  pages = {1--18},
  doi = {10.3892/ijmm.2025.5552}
}
Kostenlos starten →